Literature DB >> 9802924

Induction of anti-phospholipid autoantibodies by beta2-glycoprotein I bound to apoptotic thymocytes.

J S Levine1, R Subang, J S Koh, J Rauch.   

Abstract

The target of many anti-phospholipid autoantibodies (aPL) has been shown to be a complex between anionic phospholipid and the plasma protein beta2-glycoprotein I (beta2GPI) or the protein beta2GPI alone. As aPL binding studies have been performed almost exclusively in vitrothe identity of the natural target and/or immunogen for aPL in vivo remains undetermined. The anionic phospholipids of cell membranes represent an important potential target and immunogen for aPL. Although anionic phospholipids are normally absent from the extracellular surface of cell membranes, they redistribute from the inner to the outer leaflet during apoptosis. We have previously shown that beta2GPI binds selectively to the surface of apoptotic, but not viable, cells, and that binding of beta2GPI to the surface of apoptotic cells generates an epitope recognized by aPL from patients with primary aPL syndrome and systemic lupus erythematosus. We show here that immunization of non-autoimmune mice with beta2GPI combined with, or bound to, apoptotic cells induces aPL and lupus anticoagulant activity. Generation of aPL required heterologous beta2GPI, and occurred upon immunization with apoptotic cells and beta2GPI by three different routes of administration. Importantly, for intravenous immuniz-ations, generation of aPL occurred only when apoptotic cells and beta2GPI were injected together, but not when either was injected alone, suggesting that cell-bound beta2GPI is the true immunogen for production of aPL. Unlike other models of induced aPL, adjuvant was not an absolute requirement. Induced aPL reacted with murine, as well as bovine, beta2GPI, suggesting that heterologous beta2GPI bound to apoptotic cells can break tolerance and induce auto-antibodies reactive with autologous beta2GPI. Combined with our previous data, these results show that apoptotic cells can serve as both immunogens and natural targets for aPL. Copyright 1998 Academic Press.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9802924     DOI: 10.1006/jaut.1998.0235

Source DB:  PubMed          Journal:  J Autoimmun        ISSN: 0896-8411            Impact factor:   7.094


  10 in total

1.  Structural basis for autoantibody recognition of phosphatidylserine-beta 2 glycoprotein I and apoptotic cells.

Authors:  B A Cocca; S N Seal; P D'Agnillo; Y M Mueller; P D Katsikis; J Rauch; M Weigert; M Z Radic
Journal:  Proc Natl Acad Sci U S A       Date:  2001-11-20       Impact factor: 11.205

2.  Immunization with an apoptotic cell-binding protein recapitulates the nephritis and sequential autoantibody emergence of systemic lupus erythematosus.

Authors:  Jerrold S Levine; Rebecca Subang; Samih H Nasr; Sylvie Fournier; Ginette Lajoie; Joan Wither; Joyce Rauch
Journal:  J Immunol       Date:  2006-11-01       Impact factor: 5.422

Review 3.  Anti-phospholipid antibodies (aPL) and apoptosis: prothrombin-dependent aPL as a paradigm for phospholipid-dependent interactions with apoptotic cells.

Authors:  Joyce Rauch; Paolo D'Agnillo; Rebecca Subang; Jerrold S Levine
Journal:  Thromb Res       Date:  2004       Impact factor: 3.944

4.  Quantitative determination of the binding of beta2-glycoprotein I and prothrombin to phosphatidylserine-exposing blood platelets.

Authors:  Edouard M Bevers; Marie P Janssen; Paul Comfurius; Krishnakumar Balasubramanian; Alan J Schroit; Robert F A Zwaal; George M Willems
Journal:  Biochem J       Date:  2005-03-01       Impact factor: 3.857

Review 5.  Apoptosis and autoimmunity.

Authors:  Jeannine S Navratil; Chau-Ching Liu; Joseph M Ahearn
Journal:  Immunol Res       Date:  2006       Impact factor: 2.829

Review 6.  Dendritic cells: an important link between antiphospholipid antibodies, endothelial dysfunction, and atherosclerosis in autoimmune and non-autoimmune diseases.

Authors:  Anna Broder; Jimmy J Chan; Chaim Putterman
Journal:  Clin Immunol       Date:  2012-12-20       Impact factor: 3.969

7.  Association of mixed hematopoietic chimerism with elevated circulating autoantibodies and chronic graft-versus-host disease occurrence.

Authors:  Sylvain Perruche; Aliette Marandin; François Kleinclauss; Régis Angonin; Stéphanie Fresnay; Marie Hélène Baron; Pierre Tiberghien; Philippe Saas
Journal:  Transplantation       Date:  2006-02-27       Impact factor: 4.939

8.  Autoreactive B-1 B cells: constraints on natural autoantibody B cell antigen receptors.

Authors:  Ben Rowley; Lingjuan Tang; Susan Shinton; Kyoko Hayakawa; Richard R Hardy
Journal:  J Autoimmun       Date:  2007-09-21       Impact factor: 7.094

9.  Networks of enzymatically oxidized membrane lipids support calcium-dependent coagulation factor binding to maintain hemostasis.

Authors:  Sarah N Lauder; Keith Allen-Redpath; David A Slatter; Maceler Aldrovandi; Anne O'Connor; Daniel Farewell; Charles L Percy; Jessica E Molhoek; Sirpa Rannikko; Victoria J Tyrrell; Salvatore Ferla; Ginger L Milne; Alastair W Poole; Christopher P Thomas; Samya Obaji; Philip R Taylor; Simon A Jones; Phillip G de Groot; Rolf T Urbanus; Sohvi Hörkkö; Stefan Uderhardt; Jochen Ackermann; P Vince Jenkins; Andrea Brancale; Gerhard Krönke; Peter W Collins; Valerie B O'Donnell
Journal:  Sci Signal       Date:  2017-11-28       Impact factor: 8.192

10.  Masking of phosphatidylserine inhibits apoptotic cell engulfment and induces autoantibody production in mice.

Authors:  Kenichi Asano; Miyu Miwa; Keiko Miwa; Rikinari Hanayama; Hiroko Nagase; Shigekazu Nagata; Masato Tanaka
Journal:  J Exp Med       Date:  2004-08-09       Impact factor: 14.307

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.